Quality Assurance Magazine | Three Food Industry Trend Predictions for the Year Ahead

Our FDA Team examines the new Executive Order for promoting domestic production of critical medicines and the Food and Drug Administration’s announcement of expanding the use of surprise inspections at foreign manufacturing facilities.

Ben Wolf will present during this virtual program hosted by the Practicing Law Institute (PLI).

The Food and Drug Administration’s (FDA) recent rejection of all study data from Mid-Link Testing highlights the importance of using reliable, valid data for medical device premarket submissions. Our FDA/Food, Drug & Device Team shares best practices for applicants that engage third-party laboratories to generate data for their FDA submissions. 

Ben Wolf is quoted on the Food & Drug Administration workforce cuts’ impact on the medical technology sector.

Join Cathy Burgess for a pre-conference workshop on March 26 as she discusses “Beauty and the Law 101: Introduction to Cosmetics and Personal Care Products Law and Regulations.”

Cathy Burgess will speak on the panel “cGMPs: Discovering the Unique Role of Current Good Manufacturing Practices (cGMPs) in the Post Approval Process” at this two-day conference hosted by the American Conference Institute.

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties from compounding the drug. Our FDA/Food, Drug & Device and Health Care Groups have developed an initial checklist for providers to consider during the FDA’s enforcement discretion period.

Marc Scheineson is quoted on a Supreme Court case involving the authority of the Food and Drug Administration to regulate e-cigarettes.